Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study

Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00156858

Enrollment

200

Registered

2005-09-12

Start date

1998-01-31

Completion date

2010-12-31

Last updated

2012-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancy

Keywords

pharmacokinetics, transplantation, busulfan

Brief summary

A study of pharmacokinetics of daily intravenous busulfan

Detailed description

A study of pharmacokinetics of daily intravenous busulfan

Interventions

DRUGintravenous busulfan

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 70 Years

Healthy volunteers

Inclusion criteria

* patients undergoing transplantation

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
pharmacokinetic data	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026